Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Clinical Perspectives on Atrial Fibrillation
share announcement

Clinical Perspectives on Atrial Fibrillation

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 25 June 2025 | Viewed by 4076

Special Issue Editor

Dr. Lukasz Kuzma

E-Mail Website
Guest Editor
Department of Invasive Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland
Interests: invasive cardiology; atrial fibrillation; atrial cardiology

Special Issue Information

Dear Colleagues,

Atrial fibrillation (AF) remains a critical focus in cardiovascular research due to its increasing prevalence and complex management. Recent advancements have highlighted the importance of identifying new risk factors, such as environmental influences (e.g., air pollution), alongside established ones like chronic kidney disease (CKD), which complicates AF management and worsens outcomes. Innovative treatment approaches, including advanced catheter ablation and antiarrhythmic drugs, are expanding the therapeutic options. Precision medicine is offering tailored treatments for patients with comorbidities like CKD or those exposed to environmental risks. Additionally, AF is now frequently recognized in the context of invasive procedures, with significant implications for perioperative management, stroke prevention, and anticoagulation strategies. In this Special Issue, we welcome the submission of review articles and original research focusing on the latest advances in AF research, including novel risk factors, innovative treatments, and interactions between AF, comorbidities, and invasive procedures, alongside papers on new methods for registering and assessing AF, with the overall aim of improving AF management and patient outcomes.

Dr. Lukasz Kuzma
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atrial fibrillation
  • structural heart disease
  • interventional rhythm therapy
  • cardiac arrhythmia
  • electrocardiogram

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

41 pages, 1661 KiB  
Review
Metabolomics in Atrial Fibrillation: Unlocking Novel Biomarkers and Pathways for Diagnosis, Prognosis, and Personalized Treatment
by Justyna Rohun, Danuta Dudzik, Joanna Raczak-Gutknecht, Elżbieta Wabich, Krzysztof Młodziński, Michał J. Markuszewski and Ludmiła Daniłowicz-Szymanowicz
J. Clin. Med. 2025, 14(1), 34; https://doi.org/10.3390/jcm14010034 - 25 Dec 2024
Cited by 1 | Viewed by 1219
Abstract
Background/Objectives: Atrial fibrillation (AF) is the most frequent arrhythmia in the adult population associated with a high rate of severe consequences leading to significant morbidity and mortality worldwide. Therefore, its prompt recognition is of high clinical importance. AF detection often remains challenging due [...] Read more.
Background/Objectives: Atrial fibrillation (AF) is the most frequent arrhythmia in the adult population associated with a high rate of severe consequences leading to significant morbidity and mortality worldwide. Therefore, its prompt recognition is of high clinical importance. AF detection often remains challenging due to unspecific symptoms and a lack of reliable biomarkers for its prediction. Herein, novel bioanalytical methodologies, such as metabolomics, offer new opportunities for a better understanding of the underlying pathological mechanisms of cardiovascular diseases, including AF. The metabolome, considered a complete set of small molecules present in the organism, directly reflects the current phenotype of the studied system and is highly sensitive to any changes, including arrhythmia’s onset. A growing body of evidence suggests that metabolite profiling has prognostic value in AF prediction, highlighting its potential role not only in early diagnosis but also in guiding therapeutic interventions. By identifying specific metabolites as a disease biomarker or recognising particular metabolomic pathways involved in the AF pathomechanisms, metabolomics could be of great clinical value for further clinical decision-making, risk stratification, and an individual personalised approach. The presented narrative review aims to summarise the current state of knowledge on metabolomics in AF with a special emphasis on its implications for clinical practice and personalised medicine. Full article
(This article belongs to the Special Issue Clinical Perspectives on Atrial Fibrillation)
►▼ Show Figures

Figure 1

17 pages, 520 KiB  
Review
A Breath of Trouble: Unraveling the Impact of Air Pollution on Atrial Fibrillation
by Anna Kurasz, Gregory Y. H. Lip, Sławomir Dobrzycki and Łukasz Kuźma
J. Clin. Med. 2024, 13(23), 7400; https://doi.org/10.3390/jcm13237400 - 4 Dec 2024
Viewed by 1643
Abstract
Air pollution is a pervasive global challenge with profound implications for public health. This review explores the intricate relationship between air pollution and atrial fibrillation (AF), a prevalent cardiac arrhythmia associated with significant morbidity and mortality. Drawing on a comprehensive analysis of the [...] Read more.
Air pollution is a pervasive global challenge with profound implications for public health. This review explores the intricate relationship between air pollution and atrial fibrillation (AF), a prevalent cardiac arrhythmia associated with significant morbidity and mortality. Drawing on a comprehensive analysis of the existing literature, this review synthesizes current evidence linking various air pollutants, including particulate matter, nitrogen dioxide, ozone, and carbon monoxide, to the development and exacerbation of AF. The review delves into the role of air pollution as a global health issue alongside its specific sources, such as traffic-related emissions and industrial pollutants. It also examines the underlying mechanisms through which air pollution may contribute to the pathogenesis of AF, encompassing oxidative stress, inflammation, and autonomic nervous system dysregulation. In addition, it explores the impact of individual pollutants and the results of meta-analyses. It considers the results of vulnerable populations, including sex differences between the individuals and those with pre-existing cardiovascular conditions, who may be disproportionately affected. We also address critical research gaps in this area. Overall, air pollution has been increasingly recognized as a significant trigger for AF, with evidence linking exposure to particulate matter and gaseous pollutants to an increased incidence in short- as well as long-term exposure, highlighting the need for targeted public health interventions and further research to mitigate its cardiovascular impact. Full article
(This article belongs to the Special Issue Clinical Perspectives on Atrial Fibrillation)
►▼ Show Figures

Figure 1

Other

Jump to: Review

17 pages, 290 KiB  
Case Report
Wearable Cardioverter Defibrillator as a Treatment in Patients with Heart Failure of Various Aetiologies—A Series of Ten Cases Within the BIA-VEST Registry
by Małgorzata Kazberuk, Piotr Pogorzelski, Łukasz Kuźma, Anna Kurasz, Magdalena Róg-Makal, Urszula Matys, Justyna Tokarewicz, Paweł Kralisz and Sławomir Dobrzycki
J. Clin. Med. 2024, 13(24), 7686; https://doi.org/10.3390/jcm13247686 - 17 Dec 2024
Viewed by 881
Abstract
Background/Objectives: Sudden cardiac death (SCD) remains a major global health concern and represents one of the most common causes of mortality due to cardiovascular diseases. The wearable cardioverter–defibrillator (WCD) is an innovative, non-invasive medical device designed to provide continuous heart monitoring and immediate [...] Read more.
Background/Objectives: Sudden cardiac death (SCD) remains a major global health concern and represents one of the most common causes of mortality due to cardiovascular diseases. The wearable cardioverter–defibrillator (WCD) is an innovative, non-invasive medical device designed to provide continuous heart monitoring and immediate defibrillation in patients at risk for SCD. The study aimed to assess the efficacy of WCD usage in patients awaiting decision on therapy with implantable cardioverter–defibrillators (ICDs). Methods: We explored the clinical applications, benefits, and limitations of WCD usage within the BIA-VEST registry in Poland over the years 2021–2023. The study included 10 patients with a mean age of 49.1 ± 12.02 years. Results: All patients demonstrated good tolerance and compliance with the LifeVest WCD, wearing it for an average of 93.1 days, about 22.8 h per day (95.7% of the time). No interventions from LifeVests were recorded, and there were no effective, ineffective, or inadequate discharges. After the first follow-up echocardiography, five patients still required ICDs. Due to improved LVEF and overall condition in six out of ten patients undergoing WCD bridge therapy, ICD implantation was finally waived. Conclusions: The WCD acts as a bridge to therapy, such as ICD implantation or cardiac surgery, and may be particularly beneficial for patients with transient or evolving conditions, such as structural heart diseases and life-threatening ventricular arrhythmias. Full article
(This article belongs to the Special Issue Clinical Perspectives on Atrial Fibrillation)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop